• 1
    Frerichs FT, Murchison C, Trans. A Clinical Treatise on Diseases of the Liver. Vol 1. London: New Sydenham Society, 1860: 193246.
  • 2
    Basile AS, Jones EA, Skolnick P. The pathogenesis and treatment of hepatic encephalopathy: evidence for the involvement of benzodiazepine receptor ligands. Pharm Rev 1991; 43: 2771.
  • 3
    Butterworth RF. Neurobiology of hepatic encephalopathy. Semin Liver Dis 1996; 16: 235244.
  • 4
    Bergasa NV, Jones EA. The pruritus of cholestasis. Potential pathogenic and therapeutic implications of opioids. Gastroenterology 1995; 108: 15821588.
  • 5
    Bergasa NV, Ailing DW, Talbot TL, Swain MG, Yurdaydin C, Turner ML, Schmitt JM, et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med 1995; 123: 161167.
  • 6
    Jones EA. Fatigue associated with chronic liver disease: a riddle wrapped in a mystery inside an enigma. Hepatology 1995; 22: 16061608.
  • 7
    Witt-Sullivan H, Heathcote J, Cauch K, Blendis L, Ghent C, Katz A, Milner R, et al. The demography of primary biliary cirrhosis in Ontario, Canada. Hepatology 1990; 12: 98105.
  • 8
    Swain MG, Marie M. Improvement in cholestasis-associated fatigue with a serotonin receptor agonist using a novel rat model of fatigue assessment. Hepatology 1997; 25: 291294.
  • 9
    Weiss JM, Simson PG, Hoffman LJ, Ambrose MJ, Cooper S, Webster A. Infusion of adrenergic receptor agonists and antagonists into the locus coeruleus and ventricular system of the brain: effects on swim-motivated and spontaneous motor activity. Neuropharmacology 1986; 25: 367384.
  • 10
    Foreman MM, Fuller RW, Rasmussen K, Nelson DL, Calligaro DL, Zhang L, Barrett JE, et al. Pharmacological characterization of LY293284: a 5-HTiA receptor agonist with high potency and selectivity. J Pharm Exp Ther 1994; 270: 12701281.
  • 11
    Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977; 226: 730732.
  • 12
    Swain MG, Marie M. Defective corticotropin-releasing hormone mediated neuroendocrine and behavioral responses in cholestatic rats: implications for cholestatic liver disease-related sickness behaviors. Hepatology 1995; 22: 15601564.
  • 13
    Cauch-Dudek K, Abbey S, Stewart DE, Heathcote EJ. Fatigue and quality of life in primary biliary cirrhosis. Hepatology 1995; 22: 108A.
  • 14
    Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharm Rev 1994; 46: 158201.
  • 15
    Forster EA, Cliffe IA, Bill DJ, Dover GM, Jones D, Reilly Y, Fletcher A. A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635. Eur J Pharmacol 1995; 281: 8188.
  • 16
    Yurdaydin C, Hortnagl H, Pifl C, Steindl P, Ferenci P. Modulation of hepatic encephalopathy (HE) in rats due to thioacetamide induced acute liver failure by serotonin agonist and antagonists. Gastroenterology 1989; 96: A675.
  • 17
    Cervo L, Grignaschi G, Samanin R. 8-Hydroxy-2-(di-N-propylamino) tetralin, a selective serotonin1A receptor agonist, reduces immobility of rats in the forced swimming test by acting on the nucleus raphe dorsalis. Eur J Pharmacol 1988; 158: 5359.
  • 18
    Wieland S, Lucki I. Antidepressant-like activity of 5-HT1A agonists measured with the forced swim test. Psychopharmacology 1990; 101: 497504.
  • 19
    Herneth AM, Puspok A, Steindl P, Ferenci P. Pharmacologic modulation of hepatic encephalopathy (HE) by central-acting serotonin (5HT) receptor ligands. Gastroenterology 1994; 106: A906.
  • 20
    Doods HN, Boddeke HW, Kalkman HO, Hoyer D, Mathy MJ, Van Zwieten PA. Central 5-HT1A receptors and the mechanism of the central hypotensive effect of (+)8-OH-DPAT, DP-5-CT, R28935 and urapidil. J Cardiovasc Pharmacol 1988; 11: 432437.
  • 21
    Dreteler GH, Wouters W, Toorop GP, Jansen JAP, Saxena PR. Systemic and regional hemodynamic effects of the 5-hydroxytryptamine1A receptor agonists flesinoxan and 8-hydroxy-2(di-N-propylamino)tetralin in the conscious rat. J Cardiovasc Pharmacol 1991; 17: 488493.
  • 22
    Schworer H, Hartmann H, Ramadori G. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain 1995; 61: 3337.
  • 23
    Sanger GJ, Twycross R. Making sense of emesis, pruritus, 5-HT and 5HT3 receptor antagonists. Prog Palliative Care 1996; 4: 78.
  • 24
    Kiefel JM, Cooper ML, Bodnar RJ. Serotonin receptor subtype antagonists in the medial ventral medulla inhibit mesencephalic opiate analgesia. Brain Res 1992; 597: 331338.
  • 25
    Bergasa NV, Ailing DW, Vergalla J, Jones EA. Cholestasis in the male rat is associated with naloxone-reversible antinociception. J Hepatol 1994; 20: 8590.
  • 26
    Harsing LG, Yang H-YT. Serotoninergic regulation of hypothalamic metenkephalin content, In: HanninI, ed. Dynamics of Neurotransmitter Function. New York: Raven, 1984: 169176.
  • 27
    Bailey SP, Davis JM, Ahlborn EN. Neuroendocrine and substrate responses to altered brain 5-HT activity during prolonged exercise to fatigue. J Appl Physiol 1993; 74: 30063012.
  • 28
    Wilson WM, Maughan RJ. Evidence for a possible role of 5-hydroxytryptamine in the genesis of fatigue in man: administration of paroxetine, a 5-HT re-uptake inhibitor, reduces the capacity to perform prolonged exercise. Exp Physiol 1992; 77: 921924.
  • 29
    Jalan R, Gibson H, Lombard MG. Patients with PBC have central but no peripheral fatigue. Gut 1996; 39 (suppl): A30.
  • 30
    Roth BL. Multiple serotonin receptors: clinical and experimental aspects. Ann Clin Psych 1994; 6: 6778.